company background image
BRKR

BrukerNasdaqGS:BRKR Stock Report

Last Price

US$70.72

Market Cap

US$10.7b

7D

-4.6%

1Y

19.8%

Updated

16 Jan, 2022

Data

Company Financials +
BRKR fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance5/6
Financial Health5/6
Dividends0/6

BRKR Stock Overview

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally.

Bruker Competitors

Thermo Fisher Scientific

NYSE:TMO

US$234.4b

Danaher

NYSE:DHR

US$209.6b

Waters

NYSE:WAT

US$20.4b

NeoGenomics

NasdaqCM:NEO

US$3.1b

Price History & Performance

Summary of all time highs, changes and price drops for Bruker
Historical stock prices
Current Share PriceUS$70.72
52 Week HighUS$92.35
52 Week LowUS$54.46
Beta1.23
1 Month Change-9.97%
3 Month Change-8.76%
1 Year Change19.78%
3 Year Change104.87%
5 Year Change216.99%
Change since IPO206.65%

Recent News & Updates

Jan 05
What Is Bruker Corporation's (NASDAQ:BRKR) Share Price Doing?

What Is Bruker Corporation's (NASDAQ:BRKR) Share Price Doing?

Today we're going to take a look at the well-established Bruker Corporation ( NASDAQ:BRKR ). The company's stock...

Dec 21
Here's Why I Think Bruker (NASDAQ:BRKR) Is An Interesting Stock

Here's Why I Think Bruker (NASDAQ:BRKR) Is An Interesting Stock

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

Shareholder Returns

BRKRUS Life SciencesUS Market
7D-4.6%-1.8%-0.5%
1Y19.8%9.6%13.7%

Return vs Industry: BRKR exceeded the US Life Sciences industry which returned 9.6% over the past year.

Return vs Market: BRKR exceeded the US Market which returned 13.7% over the past year.

Price Volatility

Is BRKR's price volatile compared to industry and market?
BRKR volatility
BRKR Average Weekly Movement4.5%
Life Sciences Industry Average Movement8.7%
Market Average Movement6.6%
10% most volatile stocks in US Market15.9%
10% least volatile stocks in US Market2.4%

Stable Share Price: BRKR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: BRKR's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19917,400Frank Laukienhttps://www.bruker.com

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection.

Bruker Fundamentals Summary

How do Bruker's earnings and revenue compare to its market cap?
BRKR fundamental statistics
Market CapUS$10.73b
Earnings (TTM)US$270.30m
Revenue (TTM)US$2.36b

39.7x

P/E Ratio

4.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BRKR income statement (TTM)
RevenueUS$2.36b
Cost of RevenueUS$1.18b
Gross ProfitUS$1.19b
ExpensesUS$915.10m
EarningsUS$270.30m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)1.78
Gross Margin50.19%
Net Profit Margin11.44%
Debt/Equity Ratio78.0%

How did BRKR perform over the long term?

See historical performance and comparison

Dividends

0.2%

Current Dividend Yield

9%

Payout Ratio

Valuation

Is Bruker undervalued compared to its fair value and its price relative to the market?

39.68x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: BRKR ($70.72) is trading above our estimate of fair value ($61.96)

Significantly Below Fair Value: BRKR is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BRKR is good value based on its PE Ratio (39.7x) compared to the US Life Sciences industry average (39.9x).

PE vs Market: BRKR is poor value based on its PE Ratio (39.7x) compared to the US market (17.4x).


Price to Earnings Growth Ratio

PEG Ratio: BRKR is poor value based on its PEG Ratio (3.8x)


Price to Book Ratio

PB vs Industry: BRKR is overvalued based on its PB Ratio (10x) compared to the US Life Sciences industry average (3.3x).


Future Growth

How is Bruker forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

10.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BRKR's forecast earnings growth (10.6% per year) is above the savings rate (2%).

Earnings vs Market: BRKR's earnings (10.6% per year) are forecast to grow slower than the US market (13% per year).

High Growth Earnings: BRKR's earnings are forecast to grow, but not significantly.

Revenue vs Market: BRKR's revenue (5.7% per year) is forecast to grow slower than the US market (9.3% per year).

High Growth Revenue: BRKR's revenue (5.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BRKR's Return on Equity is forecast to be high in 3 years time (26.8%)


Past Performance

How has Bruker performed over the past 5 years?

12.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BRKR has high quality earnings.

Growing Profit Margin: BRKR's current net profit margins (11.4%) are higher than last year (8%).


Past Earnings Growth Analysis

Earnings Trend: BRKR's earnings have grown by 12% per year over the past 5 years.

Accelerating Growth: BRKR's earnings growth over the past year (71.6%) exceeds its 5-year average (12% per year).

Earnings vs Industry: BRKR earnings growth over the past year (71.6%) underperformed the Life Sciences industry 72.2%.


Return on Equity

High ROE: BRKR's Return on Equity (25.3%) is considered high.


Financial Health

How is Bruker's financial position?


Financial Position Analysis

Short Term Liabilities: BRKR's short term assets ($2.0B) exceed its short term liabilities ($921.2M).

Long Term Liabilities: BRKR's short term assets ($2.0B) exceed its long term liabilities ($1.1B).


Debt to Equity History and Analysis

Debt Level: BRKR's net debt to equity ratio (15.9%) is considered satisfactory.

Reducing Debt: BRKR's debt to equity ratio has increased from 52.1% to 78% over the past 5 years.

Debt Coverage: BRKR's debt is well covered by operating cash flow (40.8%).

Interest Coverage: BRKR earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Bruker current dividend yield, its reliability and sustainability?

0.23%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: BRKR's dividend (0.23%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.32%).

High Dividend: BRKR's dividend (0.23%) is low compared to the top 25% of dividend payers in the US market (3.44%).


Stability and Growth of Payments

Stable Dividend: BRKR is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: BRKR is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: BRKR is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BRKR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

  • Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

11.8yrs

Average management tenure


CEO

Frank Laukien (61 yo)

30.92yrs

Tenure

US$4,081,963

Compensation

Dr. Frank H. Laukien, Ph D., serves as the Chairman, Chief Executive Officer and President of Bruker Corporation at Bruker BioSpin GmbH since February 1991. Dr. Laukien serves as the Chairman, Chief Execut...


CEO Compensation Analysis

Compensation vs Market: Frank's total compensation ($USD4.08M) is below average for companies of similar size in the US market ($USD11.18M).

Compensation vs Earnings: Frank's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: BRKR's management team is seasoned and experienced (11.8 years average tenure).


Board Members

Experienced Board: BRKR's board of directors are considered experienced (6.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Bruker Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Bruker Corporation
  • Ticker: BRKR
  • Exchange: NasdaqGS
  • Founded: 1991
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$10.725b
  • Shares outstanding: 151.66m
  • Website: https://www.bruker.com

Number of Employees


Location

  • Bruker Corporation
  • 40 Manning Road
  • Billerica
  • Massachusetts
  • 1821
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/16 23:05
End of Day Share Price2022/01/14 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.